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1. Introduction 
Epilepsy is a debilitating disorder that affects over 50 million people worldwide, resulting in 
$15.5 billion in medical expenses and lost income/worker productivity in the United States 
every year (Patel, 2004). Epilepsy, also known as status epilepticus (SE), is described as the 
unregulated over stimulation of neurons throughout various regions of the brain. SE is 
characterized by seizures lasting for 30 or more minutes accompanied by a loss of 
consciousness. This disorder has been associated with significant rates of morbidity and 
mortality, possibly induced by neuronal damage and dysfunction (Sleven, et al., 2006). It is 
thought to be the result of an imbalance of excitatory and inhibitory input in a subset of 
neurons, which is then propagated to other regions of the brain, causing improper activation 
of multiple brain regions and uncontrolled cortical output (Rho, et al., 2004). Most patients 
are either under the age of 20 or over 65 years old, with a greater prevalence being in 
younger patients. While development of SE has a wide range of possible etiologies, whether 
spontaneously, as the direct result of trauma, brain tumors, metabolic abnormalities, or due 
to genetic predisposition, the exact mechanism(s) of the development of SE is poorly 
understood (Pellock, et al., 2001, Rho, et al., 2004).  
Oxidative stress has been associated with SE; however, it continues to be somewhat 
controversial whether it plays a causal role in the development of epilepsy or if it is simply 
the consequence of prolonged excitation (Patel, 2004). This increased excitation exerts high 
metabolic demands on cellular systems, such as Na+/K+ pumps and other ATP dependent 
mechanisms, required for maintaining normal cellular homeostasis. Mitochondria are the 
main source of ATP in neurons and mitochondrial dysfunction has been linked to many 
acute and chronic neurological disorders including Parkinson’s disease, traumatic brain 
injury, stroke/ischemia, and Alzheimer’s disease.  
Mitochondrial dysfunction is known to increase oxidative damage via increased mitochondrial 
reactive oxygen species (ROS) production, which has been shown to be a critical side effect of 
prolonged epileptic seizure and may cause increased susceptibility to subsequent seizures 
(Patel, 2002). It has also been shown that after prolonged seizure activity there is significant 
oxidative damage to mitochondrial DNA (mtDNA), which is responsible for encoding key 
proteins of the electron transport chain (ETC) required for oxidative phosphorylation and 
normal mitochondrial function (Patel and Li, 2003). Disruption of ATP production can cause 
impaired mitochondrial and plasma membrane transporter function, initiation of necrotic 
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pathways, alteration of neurotransmitter metabolism, and opening of the mitochondrial 
permeability transition pore (mPTP), ultimately leading to cellular destruction/dysfunction 
(Patel and Li, 2003, Sullivan, et al., 2005). 
2. GABA 
Gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain, 
activates Cl- and HCO3- (GABAA) or K+ (GABAB) permeable receptor ligand-gated channels 
by binding to specific GABAergic receptors on cellular membranes of neurons, thereby 
hyperpolarizing the cell and rendering it unable to fire rapid sequential action potentials 
(Czapinski, et al., 2005, Kwan, et al., 2001, Rho, et al., 2004). Deficiencies in these receptors 
are believed to play an important role in the development of epilepsy, as studies using 
various models of epilepsy indicate that modulation associated with subunits of the GABAA 
receptor cause a decreased ability to inhibit neuronal activity and cause promotion of 
neuronal hyperexcitability (Brooks-Kayal, et al., 1998, Rho, et al., 2004). There is also some 
evidence that the developmental roles of these receptor subtypes are not solely associated 
with the inhibition of neurons and, in the case of GABAA receptors, they can also act as 
excitatory inputs via GABA activation in immature neuronal networks.  
GABAB receptors are believed to be responsible for primary inhibitory effects at this early 
stage of development, although they may not be able to compensate for increases in 
excitation (Pellock, et al., 2001). The loss of GABAergic neurons and the subsequent 
improper neuronal compensatory reorganization for the lost inhibitory input or the loss of 
key GABA regulatory enzymes could alter the excitatory/inhibitory balance and lead to 
inappropriate excitatory signal propagation initiating SE (Rho, et al., 2004). Improper 
potassium regulation has also been suggested to be a potential cause of the increased 
excitability in young neurons due to its decreased clearance from the extracellular 
environment evoking repetitive neuronal discharges (Pellock, et al., 2001). Studies using 
calcium chelators (i.e. BAPTA) suggest that the loss of inhibitory neurons is due to their 
inability to properly buffer calcium, rendering these neurons unable to maintain adequate 
membrane potential, which could implicate mitochondrial involvement (Rho, et al., 2004).  
However, calcium has also been suggested to have age-specific effects on NMDA receptors 
by acting as the regulatory ion, rather than magnesium (Mg2+), due to its increased influence 
on the development of neuronal networks in the developing brain, and increased levels of 
intracellular calcium may interfere with the ability of immature neurons to make 
appropriate inhibitory connections during this critical period (Pellock, et al., 2001). This 
aberrant Ca2+ cycling effect highlights the importance of mitochondrial homeostasis due to 
their function of Ca2+ sequestration, which regulates the cytosolic concentrations in order to 
maintain proper cellular function. 
3. Excitotoxicity 
Recent studies have shown seizures to be associated with neuronal loss in various regions of 
the brain, including age-dependent damage to hippocampal regions; and it has been 
suggested that this damage is a result of prolonged excitation by excitatory amino acid 
(EAA)-induced excitotoxicity (Pellock, et al., 2001, Sullivan, 2005) (Fig. 1). During seizures 
neurons become depolarized for a prolonged period of time resulting in an increase in Na+ 
influx through voltage-dependent channels, and this prolonged increase in Na+ perpetuates 
neuronal depolarization. This increased and sustained depolarization causes the voltage 
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dependent Mg2+ block to be removed from NMDA channels, allowing them to be activated 
by glutamate thus facilitating the influx of Ca2+ and a loss of neuronal Ca2+ homeostasis 
(Pellock, et al., 2001, Rajasekaran, 2005, Sullivan, 2005).  
Whether oxidative stress is the cause or consequence of prolonged activation by EAA has 
been controversial. Studies suggest that chronic seizures result in increased oxidative stress, 
upregulation of neurotrophic factor genes, and structural rearrangement, all of which can 
contribute to increased susceptibility by inducing a chronic state of hyper-excitability (Liang 
and Patel, 2004, Patel, 2002). Key glial transporters (GLT-1 and GLAST) responsible for the 
uptake of exogenous glutamate from the extracellular environment can also be damaged by 
oxidative stress, resulting in the propagation and extension of activation by this EAA (Liang 
and Patel, 2004). 
4. Mitochondria 
Mitochondria function primarily as the major source of the energy production for the cell 
and are responsible for maintaining calcium homeostasis by sequestering excess calcium 
from the cytosol. The mitochondria perform these vital functions by shuttling electrons 
down a series of complexes in the inner mitochondrial membrane called the electron 
transport chain (ETC) and subsequently pump protons across the inner membrane from the 
matrix creating a membrane potential (ΔΨ) within the inner membrane space (Figure 2).  
This membrane potential can be used to sequester calcium through membrane channels and 
to carry out oxidative phosphorylation by complex V (ATP synthase) to produce ATP 
(Brookes, et al., 2004, Nicholls and Budd, 2000, Sullivan, et al., 2002, Sullivan, et al., 1998). A 
normal byproduct of oxidative phosphorylation is the production of ROS, which under 
normal physiological circumstances is scavenged by endogenous antioxidant systems such 
as MnSOD, Cu/ZnSOD, and glutathione (GSH) (Ilhan, et al., 2005). However, during 
trauma or prolonged epileptic seizure the production of ROS can overwhelm the 
endogenous antioxidant defense systems and cause damage to lipids, proteins, and DNA 
resulting in cellular dysfunction and subsequent neuronal loss.  
The brain is both rich in mitochondria and substantially more sensitive to insult and 
oxidative stress than any other tissue in the body because of its high metabolic demand for 
oxygen and glucose, its large amount of peroxidizable membranous polyunsaturated fatty 
acids (PUFA), poor repair/regenerative mechanisms, and high iron content (Patel, 2002, 
Rho, et al., 2004). In addition to epilepsy there has been an association between both 
oxidative damage and mitochondrial dysfunction with the development of many cognitive 
disorders, including Parkinson’s and Alzheimer’s disease (Ilhan, et al., 2005, Patel, 2002, 
Sullivan, et al., 2004). Studies showing that oxidative damage precedes seizure initiation and 
studies implementing strategies to limit free radical formation and several antioxidant 
therapies have indicated that oxidative mechanisms are involved a causal role of seizure 
induced neuronal loss. However, studies have also detected oxidative damage to 
mitochondrial complex I, as well as some integral citric acid cycle proteins, up to 44 hours 
after SE, suggesting that oxidative damage is the result of prolonged seizure activity (Gibbs, 
et al., 2006, Jung, et al., 2001, Patel and Li, 2003, Patel, 2002, Rong, et al., 1999). 
5. Antioxidative mechanisms 
Superoxide dismutase (SOD), a major component of the endogenous antioxidant system of 
the cell, has three isoforms which each have distinct localizations within the cell. 
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Cu/ZnSOD (SOD1) is primarily found in the cytosol, MnSOD (SOD2) is found in the 
mitochondria, and EC-SOD (SOD3) is found in the extracellular space (Patel and Li, 2003). 
These enzymes catalyze the dismutation of superoxide into hydrogen peroxide (H2O2) and 
oxygen (O2) at a rate very close to its diffusion rate (Ilhan, et al., 2005, Patel and Li, 2003). 
Glutathione peroxidase (GPx) and glutathione (GSH), another major component of the 
endogenous antioxidant system, catalyze H2O2 into water preventing the formation of 
hydroxyl radicals, rendering the previously dangerous superoxide species harmless to 
cellular structures (Ilhan, et al., 2005, Rho, et al., 2004).  
Glutathione levels were shown, in vitro and in vivo, to decrease as early as 4 hours after SE, 
which highlights its importance in influencing mitochondrial /cellular damage outcome 
after SE (Gibbs, et al., 2006, Sleven, et al., 2006). Studies conducted by modulating the level 
of SOD in a mouse model of epilepsy have given us insights into the role of antioxidant 
systems in the prevention of oxidative stress and a seemingly causal role of oxidative 
damage in seizure. Homozygous MnSOD -/- knockout mice are embryonic lethal, which 
highlights its vital function in physiological function and developmental processes. Using 
heterozygously expressing (-/+) or transgenic overexpressing MnSOD mice have allowed 
for the investigation of the consequences of diminished or overabundant (respectively) 
antioxidant capacity on seizure development and hippocampal damage. It has been shown 
that overexpression of MnSOD, 0.5-2 fold, can attenuate kainate induced seizures, however 
animals with diminished MnSOD levels showed an exacerbation of kainate-induced seizure 
and hippocampal damage, which was attenuated with antioxidant treatment (Patel, 2002). 
Overexpression of MnSOD also produces lower amounts of inactive aconitase and 8-
hydroxy-2-deoxyguanosine (8-OHdG), measures of oxidative protein and DNA (most likely 
mtDNA) damage, indicating a role in the preservation of mitochondrial function (Gonzalez, 
et al., 2005, Patel, 2002, Sleven, et al., 2006).  
Damage to mitochondrial complex I, α-keto-glutarate dehydrogenase, citrate synthase, 
aconitase, and GSH can be detected at time points well after the end of an epileptic episode, 
and damage to these cellular components can induce cell death cascades and increase the 
likelihood of future seizures (Gibbs, et al., 2006). Highlighting the importance of this 
oxidative damage in epileptogenic pathologies is the specific defect of complex I activity 
found in the hippocampal CA3 region of patients suffering from hippocampal sclerosis and 
intractable seizures, which was found to be sufficient enough to affect ATP production in 
this region, possibly accounting for the pathology of seizure development in these patients 
(Gibbs, et al., 2006, Kunz, et al., 2000). 
6. Antiepileptic drugs 
AEDs have been in use for the attenuation of seizures since the early part of the 20th century 
(Fig. 2). Since their inception, many pharmacological interventions have been examined for 
their efficacy in attenuating the development of epileptic seizures, however, out of the 
thousands of compounds that have been screened for their ability to treat seizure, only a 
handful of antiepileptic drugs have been approved for clinical use. It was believed that early 
AEDs, such as benzodiazepines, phenobarbital, and valproate decreased seizure prevalence 
by increasing GABA inhibition of aberrant neuronal excitation, where as newer AEDs affect 
a much broader set of cellular systems, which can increase the complexity of 
pharmacological effect (Czapinski, et al., 2005, Kwan, et al., 2001). In addition to the 
potential detrimental effect, most of these interventions focus on the prevention of future 
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seizures rather than preventing neuronal damage resulting from prolonged or multiple 
seizures. Alternative targets at the cellular level to modulate seizure incidence and, perhaps 
more importantly, attenuate neuronal damage must be developed in order to create a more 
substantial and permanent treatment for epilepsy. 
 
 
Fig. 1. Hypothetical sites of neuroprotective actions of epileptic therapeutic strategies. 
Following seizure mitochondria buffer rises in intracellular Ca2+. Excessive mitochondrial 
Ca2+ cycling results in an increase in ROS production and in the initiation of cell death. 
AEDs target hyperexcitability by two mechanisms; I.) increasing inhibitory 
neurotransmission or II.) decreasing excitatory neurotransmission. The ketogenic diet alters 
neurotransmitter metabolism which decreases neuronal excitability. Additionally, the 
ketogenic diet has been shown to increase uncoupling protein activity and in-turn reduces 
oxidative stress. Antioxidants act to decrease oxidative stress and prevent cell death.  
6.1 GABA modulators 
AEDs that modulate the action of GABA in order to increase the inhibitory effect of this 
neurotransmitter have been widely used as the first line of treatment therapies for SE 
(Gibbs, et al., 2006). These drugs include Phenobarbital (PB), Benzodiazepines (BZD), 
Vigabatrin (VGB), and Tiagabine (TGB). PB, perhaps the oldest and most studied member of 
the barbiturate family has been used since the turn of the 20th century for its properties as an 
anticonvulsant and sedative, confers anticonvulsant protection to animals subjected to 
various experimental seizure models (Kwan, et al., 2001). This type of GABA modulators 
include that also includes Methylphenobarbital, Pentobarbital, and Primidone. In addition 
to increasing the affinity of GABA for its respective receptor and the activation of chloride 
channels, PB extends the time of chloride channel opening, without affecting frequency of 
opening or channel conductance (Czapinski, et al., 2005, Kwan, et al., 2001). PB has also been 
shown to elicit their antiepileptic effect by directly blocking high-voltage-activated Ca2+ 
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channels and inhibiting AMPA/kainate receptors, preventing depolarization of neurons, 
propagation of the aberrant signals, and the cascade of damaging secondary events within 
the cell (Czapinski, et al., 2005, Kwan, et al., 2001, Pellock, et al., 2001, Sullivan, 2005). This 
AED is unique due to its ability to activate GABAA receptors in the absence of exogenous 
GABA, and that this augmentation of GABA-mediated inhibition and inhibition of 
glutamate-mediated excitation is selective for the postsynaptic terminal (Kwan, et al., 2001, 
Pellock, et al., 2001). It has also been suggested that PB locks Na+ channels, together with its 
modulation of GABA receptors it induces its anticonvulsive action by inhibition of 
glutamate activation (Pellock, et al., 2001, Rho, et al., 2004, Sullivan, 2005, Trojnar, et al., 
2002). PB has showed great efficacy in attenuating seizure and is generally a safe medication 
with a prolonged treatment duration of action, however, there are still cognitive and 
behavioral side effects, as well as increased hepatic enzyme activation effecting the 
concomitant administration of additional AEDs, limiting its use in some situations (Gibbs, et 
al., 2006, Pellock, et al., 2001). There have been conflicting studies describing PB as both 
neuroprotective and neurodegenerative after SE, however its neurodegenerative effect may 
be isolated to the developing brain where mitochondrial degeneration, deficits in 
hippocampal based behavior measurements, and myelin degradation have been found with 
PB administration early in life (Sankar and Holmes, 2004, Trojnar, et al., 2002).  
Along with PB, Benzodiazepines, which have more than 50 distinct family members 
including Diazepam, Loarazapam, Midazolam, and Clonazepam, represent the first line 
treatments for SE and have abroad spectrum of clinical activity used mainly for partial and 
idiopathic generalized epilepsies, complex seizures, secondary generalized motor seizures, 
and acute SE (Gibbs, et al., 2006, Pellock, et al., 2001). This class of drugs also bind to the 
GABAA receptor subtype at the allosteric binding site on the α-subunit inducing an increase 
in the frequency of Cl- channel opening, however they are unable to activate these receptors 
in the absence of endogenous GABA (Czapinski, et al., 2005, Gibbs, et al., 2006, Granja, et al., 
1997, Pellock, et al., 2001). It has also been shown that BZDs can also block Na+ channels at 
high concentrations encountered during intensive treatment of acute SE (Czapinski, et al., 
2005).They work to lower seizure threshold in order to decrease the duration of erroneous 
discharges thereby limiting the spread of the aberrant excitation to adjacent brain regions. 
This type of AED is marked for its consistency in efficacy, however they are susceptible to 
tolerance development and have been shown to exacerbate neuronal damage in some 
experimental models, limiting their use in chronic seizure disorder patients (Gibbs, et al., 
2006, Pellock, et al., 2001). Much like the action of PB, these drugs seem to have an altered 
neuroprotective function depending on neuronal development, where as in mature animals 
BZDs have been shown to be neuroprotective, in immature animals these same compounds 
show a dose-dependent induction of apoptotic cell death (Sankar and Holmes, 2004, 
Sullivan, 2005, Trojnar, et al., 2002).  
Vigabatrin and Tiagabine were designed as a new generation of novel AED intended to 
regulate GABA metabolism by either acting as an irreversible inhibitor of (GABA-T) GABA 
transaminase (VGB) or inhibiting glial/neuronal uptake of GABA (TGB) both resulting in 
increased and prolonged duration of GABA signaling (Czapinski, et al., 2005, Kwan, et al., 
2001, Pellock, et al., 2001, Trojnar, et al., 2002). VGB, a structural GABA analogue, actually 
uses GABA-T to enzymaticly transform in to its active metabolite, which then irreversibly 
binds to GABA-T and acts to inhibit its ability to degrade GABA, causing a prolonged 
increase in GABA levels throughout the brain, without manipulating any other GABA 
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synthesis or metabolic enzymes (Kwan, et al., 2001). TGB inhibits GABA reuptake from the 
synaptic cleft by selectively blocking the GAT-1, a GABA transporter, without affecting 
GAT-2, GAT-3, or GBT-1; allowing its affects to be localized primarily to the cerebral cortex 
and the hippocampus (Kwan, et al., 2001). Both TGB and VGB were designer drugs targeted 
at specific aspects of the GABAergic system and have been shown to be protective against 
seizure and neurodegeneration; however, like PB and BDZ there is also evidence that they 
are detrimental to the developing nervous system (Kwan, et al., 2001, Pellock, et al., 2001, 
Trojnar, et al., 2002). VGB administration for refractory epilepsy in children and infantile 
spasms has presented a pronounced prevalence (~40%) retinal toxicity and development of 
visual field defects, and as a result its use has declined worldwide in younger patients 
(Czapinski, et al., 2005, Kwan, et al., 2001, Pellock, et al., 2001).  
With any AEDs whose primary action is prolonging the duration of inhibition by the 
GABAergic system, symptoms such as, drowsiness, dizziness, agitation, amnesia, fatigue, 
depression, weight gain, ataxia, and nystagmus are prevalent in patients with prolonged 
use. These drugs have been shown to be efficacious in attenuating seizures and have shown 
potential in promoting neuroprotection; however, the key to their effectiveness will be the 
regulation of their administration to children due to their age specific effects on the 
developing brain. 
6.2 Ion channel modulators 
Recently developed AEDs have been designed to modulate specific ion channels to prevent 
aberrant and prolonged excitation. Na+ channels blockers such as Phenytoin (PHT) and 
Carbamazepine (CBZ), Ca2+ blockers such as Ethosuximide (ESM), or Na+/Ca2+ (L-Type) 
channel blockers such as Lamotrigine (LTG), Oxcarbazepine (OXC), and Zonisamide (ZNS), 
were introduced to replace the sedative GABAergic modulating AEDs (Czapinski, et al., 
2005, Kwan, et al., 2001, Pellock, et al., 2001, Sullivan, 2005). Blockage of Na+ channels 
reduces the ability of neurons to undergo multiple rapid excitations resulting in increased 
instances of prolonged depolarization propagated by the activation of voltage-dependent 
Na+ channels, and increased cellular swelling via Cl- influx, ultimately leading to cellular 
damage and dysfunction (Kwan, et al., 2001, Sullivan, 2005). Increased Ca2+ influx is also a 
result of prolonged excitation, which causes increased excitatory amino acid (EAA) release 
from the presynaptic membrane into the synaptic cleft, resulting in further dissemination 
the aberrant excitatory activation to surrounding brain regions, inducing cellular damage 
via secondary signaling cascades (Brookes, et al., 2004, Kwan, et al., 2001, Nicholls and 
Budd, 2000, Nicholls and Ferguson, 2002, Pellock, et al., 2001). 
PHT and CBZ share the selective mechanism of Na+ channel inhibition, which decreases the 
frequency of depolarization, thereby decreasing the amount of irregular signal 
transmissions. In the case of PHT, it is the most effective when there is a high frequency of 
depolarization, which is an important feature of this mechanism; instead of completely 
inhibiting activation it works to minimize only excessive neuronal activity (Kwan, et al., 
2001). Also, PHT is generally the most well tolerated AED, side effects are common due to 
its unique non-linear elimination kinetics, but these symptoms can normally be attenuated 
with proper dose adjustments (Pellock, et al., 2001). There are also a few reports suggesting 
that PHT functions by blocking high voltage Ca2+ channels and may be involved in 
GABAergic modulation, however this evidence has yet to be fully substantiated (Granger, et 
al., 1995, Kwan, et al., 2001, Rowley, et al., 1995). CBZ, which is effective in focal (partial) 
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and grand mal (tonic-clonic) seizures and exclusively blocks Na+ channels, seems to be less 
effective as a neuroprotective agent than other anticonvulsant compounds in treating SE, 
but was shown to have increased protection for ischemia/traumatic insult (Czapinski, et al., 
2005, Pellock, et al., 2001). Neurotoxicity of CBZ, like PHT, was only found when the 
administrated dose was at supra-therapeutic concentrations (Czapinski, et al., 2005, Pellock, 
et al., 2001, Sullivan, 2005).  
OXC is a structural analogue of CBZ, however due to modifications designed to prevent the 
production of the 10,11-epoxide metabolite, it is more easily tolerated by the patient and 
shows a decreased level of side effects compared to CBZ (Kwan, et al., 2001, Pellock, et al., 
2001). It has the ability to block both Na+ and L-type Ca2+ channels, and has an additional 
possibly unique function of increasing K+ channel conductance, all of which leads to 
decreased excitation and excitotoxic signaling cascades (Czapinski, et al., 2005, Kwan, et al., 
2001, Pellock, et al., 2001). Retigabine (RTB) functions as an anticonvulsant by decreasing the 
activation threshold of neurons via activation of K+ channels and increasing GABA-
mediated Cl- currents (Czapinski, et al., 2005). ZNS, which is one of the only drugs 
specifically evaluated for the pediatric patient population, also blocks both Na+ and Ca2+ 
channels, GABA receptor linked Cl- channels, enhances dopaminergic/serotonergic 
neurotransmission, and inhibits glutamate-induced excitation (Czapinski, et al., 2005, Kwan, 
et al., 2001, Pellock, et al., 2001). In addition to its antiepileptic and anticonvulsant effects, 
ZNS also decreases the production of exogenous nitric oxide and free radicals, giving it a 
unique neuroprotective quality against oxidative stress resulting from prolonged SE 
(Czapinski, et al., 2005). LTG is a novel AED, effective in blocking both Na+ (primarily slow 
inactivated state) and L-type Ca2+ channels, which is efficacious in treating partial, absence, 
myoclonic and tonic-clonic seizures (Kwan, et al., 2001, Pellock, et al., 2001, Trojnar, et al., 
2002). ESM is unique from other ion channel modulators in that it is specific for T-type Ca2+ 
channel blockage, and does not have any other known mechanism (Kwan, et al., 2001). It has 
been used for many years for generalized absence seizures, due to its ability to prevent the 
characteristic T-type Ca2+ channel induced synchronized 3-Hz spike-and-wave discharge 
(Kwan, et al., 2001). 
6.3 Multi-mechanistic AEDs 
There have been many AEDs developed with multiple mechanisms of action to attenuate 
seizure activity. One of the most studied and widely used multi-mechanistic AED is 
valproic acid (VPA), however, the exact mechanism of its anticonvulsant action is still 
debated, and in fact may be a number of different mechanisms (Kwan, et al., 2001, Pellock, 
et al., 2001). It has proven to be effective in treating a range of disorders in addition to 
epilepsy, including bipolar effective disorder and migraine headaches (Schulpis, et al., 2006). 
The possible mechanisms include, the modulation of the GABAergic system by modulation 
of either inhibition of GABA-T and succinic semialdehyde dehydrogensase or the increase of 
glutamic acid dehydrogenase, which work to either inhibit GABA breakdown or elevate 
GABA synthesis (respectively), however the later is thought unlikely to be the primary 
mechanism (Czapinski, et al., 2005, Pellock, et al., 2001). VPA has also been shown to block 
voltage-dependent Na+ channels, thereby reducing sustained repetitive firing of neurons, 
however it does not exert an effect on the recovery of Na+ channels from the inactivated 
state (Kwan, et al., 2001, Pellock, et al., 2001). This AED also has similar effects on T-type 
Ca2+ channels as does ESM, which may account for its efficacy in specifically treating 
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absence seizures (Kwan, et al., 2001, Trojnar, et al., 2002). However, recent studies have 
shown that chronic VP administration can cause some side effects including increased free 
radical formation (ROS) and oxidative DNA damage, impairment of liver mitochondrial 
function, hepatotoxicity, and increased serum lipids, lipoproteins and Apo lipoproteins 
increasing the risk of cardiovascular problems (Karikas, et al., 2006, Schulpis, et al., 2001, 
Schulpis, et al., 2006).  
 GBP is a structural analogue of GABA designed to be a blood brain barrier permeable 
mimetic of GABA activation of GABA receptors inducing an increase in the activation of the 
GABAergic system. However, studies using binding assays show that there is not affinity 
for GBP for either GABAA or GABAB receptors; instead there is evidence that GBP acts 
through interactions with the L-amino acid transport system, reducing high frequency 
action potential firing via Na+ channel blockage, possible modulation of GABA metabolism, 
and blockage of L-type voltage dependent Ca2+ channels (Czapinski, et al., 2005, Kwan, et 
al., 2001, Pellock, et al., 2001). Both Felbamate (FBM) and Topiramate (TPM), also multi-
mechanistic AEDs, can inhibit neuronal activation by the EAA glutamate (Czapinski, et al., 
2005). FBM, which is used clinically to treat a wide variety of seizure disorders, can have 
dual actions on excitatory and inhibitory neuronal mechanisms, as highlighted by the 
conflicting studies showing the lack of ligand binding to the GABA receptor and increases 
in GABA-mediated responses, as well as the inhibition of NMDA-linked excitation (Pellock, 
et al., 2001). TPM, however, has clearly been shown to block Na+ channels, increase 
GABAergic-mediated inhibition, and antagonize glutamate activation of both NMDA and 
AMPA/kainate receptors (Pellock, et al., 2001). Both FBM and TPM have good clinical 
efficacy in reducing seizure and have a low incidence of tolerance development, which 
makes these AEDs more ideal for the treatment of chronic epileptic disorders. 
6.4 Unknown mechanism 
There are still more compounds being investigated for their potential antiepileptic 
properties, however the mechanism of some of these AEDs have not fully been elucidated. 
One such compound, Levetiracetam (LEV), is an analogue of piracetam and has been used 
and has shown great promise as an anticonvulsant pharmacological therapy; however, its 
exact mechanism of conferring this anticonvulsant action is currently known. Studies have 
shown that LEV has little to no effect on increasing the inhibitory effect of the GABAergic 
system, and it has been inferred that it has a completely unique activity profile that is unlike 
any of the AEDs mechanisms that have come before it, including Na+ and Ca2+channel 
blockage, K+ channel activation, and GABA/glutamate system modulation (Gibbs, et al., 
2006, Kwan, et al., 2001, Pellock, et al., 2001). Perhaps the most interesting property of LEV is 
that it has exhibited neuroprotective effects after experimentally induced SE; and has been 
shown to attenuate seizure severity. In addition to this attenuation, decrease damage to 
many vital mitochondrial proteins, such as α-keto-glutarate dehydrogenase, complex I, 
Aconitase, citrate synthase, and GSH has been shown with LEV treatment; which seems 
indicate an ability to attenuate oxidative damage and mitochondria dysfunction resulting 
from prolonged seizure induced excitation (Kwan, et al., 2001, Mazarati, et al., 1998). This 
suggests that LEV acts to not only prevent the damaging epileptic episode, but also to 
promote intracellular/intramitochondrial reparative mechanisms. The elucidation of this 
mechanism of anticonvulsive neuroprotection is could result in a wider administration of 
LEV, and has the potential to lead to the development of an entirely new class of AEDs with 
similar neuroprotective effects. 
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Fig. 2. Effects of commonly used AEDs. 
7. Antioxidants 
Antioxidant therapy following seizure has been shown to be beneficial (Acharya, et al., 
2008). Resveratrol is a naturally occurring antioxidant and has been shown to decrease 
hippocampal neuronal cell death and decrease mossy fiber sprouting following kainite-
induced temporal lobe epilepsy (Wu, et al., 2009). Other antioxidants, such as ascorbic acid 
and α-tocopherol, have been shown to decrease neuronal cell death following seizure 
induced with pilocarpine (Tome Ada, et al., 2010). Additionally, the naturally occurring 
antioxidant melatonin has been shown to be neuroprotective in human epilepsy (Molina-
Carballo, et al., 1997). Thus, oxidative stress is one potential target for neuroprotective 
intervention following seizure. 
8. Alternative non-pharmacological treatments 
An alternative to pharmacological interventions is the implementation of the ketogenic diet 
(KD), originally designed physiological effects that occur as a result of fasting, such as 
ketosis, in order to mimic its protective outcomes. Fasting, which has been used for 
centuries as an unproven method for controlling seizure disorders, primarily results in 
increased levels of ketone bodies and causes the body begin using stored fat as the primary 
energy source as opposed to glucose (Thiele, 2003, Ziegler, et al., 2003). The KD was 
developed as way to mimic both the increase in ketone bodies and shift of metabolic 
utilization without depriving patients of essential nutrients and energy. The regime requires 
a shift in the ratio of fat: carbohydrate consumption from roughly 1:2 to 4:1 (Rho, et al., 2004, 
Thiele, 2003). Many versions of the ketogenic diet have been examined for efficacy in 
attenuating seizure, of which the program shown to have the best efficacy is a reduced 
calorie regime combined with the increased fat: carbohydrate ratio (Rho, et al., 2004).  
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Although, the mechanism of the KD is not fully understood; it has been shown to increase 
antioxidant enzymes, such as glutathione peroxidase (GPx), as well as upregulate 
specialized mitochondrial uncoupling proteins (fig. 3) thereby reducing ROS and oxidative 
damage by supporting the endogenous antioxidant system as well as decreasing the amount 
of ROS actually produced. (Sullivan, et al., 2004). The reduction of ROS and oxidative 
damage, coupled with preferential utilization of an efficient energy source (ketone bodies), 
in neuronal tissue could explain how this treatment proves to be an effective therapy for 
epileptic seizure, however, the rigorous constraints on caloric intake has been a stumbling 
block for its wide spread implementation, most patients opting for an alternative 
pharmacological treatment (Rho, et al., 2004) 
 
 
Fig. 3. This is a schematic of the mitochondrial electron transport chain (ETC). Electrons are 
donated by reducing agents (NADH and FADHH) which flow down the ETC causing the 
pumping of protons (H+) into the intermembrane space, thereby creating a proton gradient 
(separation of charge). It is by this mechanism that the cell is able to produce energy in the 
form of ATP by utilizing this proton gradient to phosphorylate ADP to ATP via Complex V 
(ATPsynthase). Oxidative phosphorylation produces reactive oxygen species (ROS) as a 
normal byproduct of physiological function. ROS is mostly produced at Complex I; however 
it can be produced at Complex III/IV (via the same mechanism pictured at Complex I) as 
well. Endogenous antioxidant systems such as GSH and MnSOD prevent the formation of 
peroxynitrite (ONOO.) which can lead to mitochondrial and cellular damage/dysfunction. 
Uncoupling Proteins (UCP) can dissipate the proton gradient by translocating protons from 
the intermembrane space to the mitochondrial matrix in response to activation by free fatty 
acids (FFA). 
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9. Conclusion 
Most of the AEDs discussed in this chapter are effective treatments for a wide range of 
seizure disorders; however each has their distinct pros and cons. There are some AEDs that 
are better to administer in a pediatric setting, where as others will work better for patients 
with chronic seizure disorders. Most, if not all, depend on the proper dosing to achieve their 
optimum treatment effect. Only when the therapeutic dose is surpassed is there an increased 
risk of potential side effects that may terminate that avenue of treatment options. 
It has been shown that there is a correlation between seizure development and oxidative 
damage, which in turn causes a state of hyper-excitability causing the initiation of future 
seizures due to the increased sensitivity to excitation. It has become apparent that 
mitochondria are intimately involved in this mechanism due to the involvement of 
mitochondrial superoxide dismutase (MnSOD) in the attenuation of seizure induced 
oxidative damage (Liang and Patel, 2004). The attenuation of this oxidative damage could 
lead to a decrease in the initiation of prolonged seizures and further oxidative damage, 
thereby ending this vicious cycle. Therapeutic interventions and AEDs designed to 
attenuate oxidative damage and decrease the total level of excitation to reduce the incidence 
of seizure and the amount of subsequent damage will be the most beneficial. AEDs that 
provide neuroprotection, in addition to their anticonvulsant properties, are currently in use 
and should be further studied so that other treatments may be developed with 
neuroprotection, not only attenuation of SE, in mind. 
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